Ignite Creation Date:
2024-05-05 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00433914
Status:
COMPLETED
Last Update Posted:
2015-03-06
First Post:
2007-02-09
Brief Title:
Safety Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine When Administered to Healthy Infants
Sponsor:
Novartis Vaccines
Organization:
Novartis
Study Overview
Official Title:
A Phase 2 Single Blind Single Center Randomized Study of the Safety Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine - OMV When Administered to Healthy Infants 6-8 Months Old
Status:
COMPLETED
Status Verified Date:
2015-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To explore safety Tolerability and immunogenicity of two formulations of a Meningococcal B Recombinant Vaccine when administered to healthy infants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Eudract Number 2006-005589-38 | None | None | None |